GelrinC™

SAGE Clinical Study by Regentis Biomaterials

What is the GelrinC SAGE Clinical Study?

GelrinC™

Study Overview

Regentis Biomaterials is conducting a pivotal clinical study (research study) to evaluate the safety and efficacy of an investigational device, GelrinC, implanted following a standard microfracture procedure, compared to a historical control group of patients who have undergone microfracture for the treatment of articular cartilage defects of the knee.

This is a non-randomized study, which means that all patients who meet the eligibility criteria and volunteer to participate in the study will receive GelrinC treatment.

More about the GelrinC SAGE Study

Your participation in the study is completely voluntary; if you are interested in participating in the SAGE Study and meet the eligibility criteria, your decision to participate is completely voluntary.

All patients meeting the SAGE Study eligibility criteria who volunteer to participate will receive GelrinC; there will be no randomization to an alternative treatment.

This is an **FDA regulated clinical study** and specific criteria must be followed to determine who is eligible for inclusion. Only when a study investigator (surgeon) has determined a patient to be eligible and the patient has volunteered to participate after learning about the potential benefits and risks, can they be entered into the study.

Click to find out if you may be eligible for the SAGE study

CAUTION: Investigational Device. Limited by Federal (USA) Law to Investigational Use.

Regentis Biomaterials

 | About Regentis | Terms of Use | Privacy Policy | Version: February 2018